Journal
LUNG
Volume 200, Issue 5, Pages 539-547Publisher
SPRINGER
DOI: 10.1007/s00408-022-00571-w
Keywords
Pulmonary fibrosis; Alveolar epithelial type 2 cell dysfunction; Metabolic reprogramming; Transitional state
Categories
Funding
- National Natural Science Foundation of China [82000065]
- Beijing Key Clinical Specialty Construction Project [2020-2022]
Ask authors/readers for more resources
Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible pulmonary disease with unclear pathogenesis and limited treatment options. Dysfunction of alveolar epithelial type 2 (AT2) cells is associated with the development of IPF, involving senescence, apoptosis, stress, damage, and metabolic reprogramming. Potential treatments targeting AT2 cell dysfunction are summarized.
Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible pulmonary interstitial disease that seriously affects the patient's quality of life and lifespan. The pathogenesis of IPF has not been clarified, and its treatment is limited to pirfenidone and nintedanib, which only delays the decline of lung function. Alveolar epithelial type 2 (AT2) cells are indispensable in the regeneration and lung surfactant secretion of alveolar epithelial cells. Studies have shown that AT2 cell dysfunction initiates the occurrence and progression of IPF. This review expounds on the AT2 cell dysfunction in IPF, involving senescence, apoptosis, endoplasmic reticulum stress, mitochondrial damage, metabolic reprogramming, and the transitional state of AT2 cells. This article also briefly summarizes potential treatments targeting AT2 cell dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available